Intensity Therapeutics Inc. (INTS) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Intensity Therapeutics, Inc. Common stock

NASDAQ | INTS

0.32

USD

+0.00 ( +0.00%)

AT CLOSE (AS OF Jun 13, 2025)

$11M

MARKET CAP

P/E Ratio

-1.26

EPS

$5.1

52 Week High

$0.28

52 Week Low

LIFE SCIENCES

Sector

INTS Chart

Recent Chart

Price Action

Candles

INTS Technicals

Tags:

INTS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$17M
Selling General And Administrative	$6.1M
Research And Development	$10M
Operating Expenses	$17M
Investment Income Net	-
Net Interest Income	$314K
Interest Income	$314K
Interest Expense	$0
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$25K
Income Before Tax	-$16M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$16M
Comprehensive Income Net Of Tax	-
Ebit	-$16M
Ebitda	-$16M
Net Income	-$16M

Revenue & Profitability

Earnings Performance

INTS Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$4.8M
Total Current Assets	$3.4M
Cash And Cash Equivalents At Carrying Value	$2.6M
Cash And Short Term Investments	$2.6M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$1.4M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$0
Other Current Assets	$773K
Other Non Current Assets	-
Total Liabilities	$1.9M
Total Current Liabilities	$1.8M
Current Accounts Payable	$1.2M
Deferred Revenue	-
Current Debt	-
Short Term Debt	$56K
Total Non Current Liabilities	$110K
Capital Lease Obligations	$138K
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$138K
Other Current Liabilities	$508K
Other Non Current Liabilities	-
Total Shareholder Equity	$2.9M
Treasury Stock	-
Retained Earnings	-$67M
Common Stock	$2K
Common Stock Shares Outstanding	$14M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$15M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	-
Capital Expenditures	$0
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$2.9M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$16M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$17M
Selling General And Administrative	$6.1M
Research And Development	$10M
Operating Expenses	$17M
Investment Income Net	-
Net Interest Income	$314K
Interest Income	$314K
Interest Expense	$0
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$25K
Income Before Tax	-$16M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$16M
Comprehensive Income Net Of Tax	-
Ebit	-$16M
Ebitda	-$16M
Net Income	-$16M

INTS News

INTS Profile

Intensity Therapeutics, Inc. Common stock Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

None